Bis(4-tert-butylphenyl)-1,3-thiazol-2-amine

Catalog No.: 
ACZHXU189
CAS No.: 
554405-20-8
Molecular Formula: 
C23H28N2S
Molecular Weight: 
364.56
Bis(4-tert-butylphenyl)-1,3-thiazol-2-amine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$100.00InquiryInquiry
100mg95%$141.00InquiryInquiry
250mg95%$194.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameBis(4-tert-butylphenyl)-1,3-thiazol-2-amine
IUPAC Name4,5-bis(4-(tert-butyl)phenyl)thiazol-2-amine
MDL No.MFCD03965931
Molecular FormulaC23H28N2S
Molecular Weight364.56
SMILESNC1=NC(C2=CC=C(C(C)(C)C)C=C2)=C(C3=CC=C(C(C)(C)C)C=C3)S1
InChI KeyNVGFIKJZRWPKDF-UHFFFAOYSA-N
Synonym2-Thiazolamine, 4,5-bis[4-(1,1-dimethylethyl)phenyl]-;Bis(4-tert-butylphenyl)-1,3-thiazol-2-amine
CAS No.554405-20-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACZHXU189 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZHXU189 route product structure diagram
    ACZHXU189554405-20-8
Inquiry

2. ACZHXU189 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZHXU189 route product structure diagram
    ACZHXU189554405-20-8
Inquiry

3. ACZHXU189 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACZHXU189 route product structure diagram
    ACZHXU189554405-20-8
Inquiry

Comments (0)